Trinity Biotech (Trinity Biotech) ROE % Adjusted to Book Value : 0.00% (As of Sep. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Trinity Biotech ROE % Adjusted to Book Value?

Trinity Biotech's ROE % for the quarter that ended in Sep. 2023 was 0.00%. Trinity Biotech's PB Ratio for the quarter that ended in Sep. 2023 was N/A. Trinity Biotech's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 was N/A.

Trinity Biotech ROE % Adjusted to Book Value Historical Data

The historical data trend for Trinity Biotech's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech ROE % Adjusted to Book Value Chart

Trinity Biotech Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-37.10

-25.89

Negative Equity

Trinity Biotech Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-51.74	-	-	-	-

Competitive Comparison of Trinity Biotech's ROE % Adjusted to Book Value

For the Diagnostics & Research subindustry, Trinity Biotech's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Trinity Biotech's ROE % Adjusted to Book Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Trinity Biotech's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Trinity Biotech's ROE % Adjusted to Book Value falls into.

Trinity Biotech ROE % Adjusted to Book Value Calculation

Trinity Biotech's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Trinity Biotech's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Trinity Biotech ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Trinity Biotech (Trinity Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

TRBA:Germany

Address

IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8

Website

https://www.trinitybiotech.com

Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.